Stock listing
NASDAQ:OKYO OKYO Pharma Limited Stock
Home listing (NASDAQ) of OKYO Pharma Limited
Follow OKYO Pharma Limited into a list and get an email when it puts out news.
Share price · NASDAQ:OKYO
$1.07 USD -0.03 (-2.7%)
Close on Nov 20, 2026
- Day range
- $1.04 – $1.25 USDNov 20, 2026
- Volume
- 76,391 sharesNov 20, 2026
- Market cap
- $56.15M USDAt the close on Nov 20, 2026 · price × 52.48M shares outstanding
- 52-week range
- $1.04 – $3.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $169,207 USDMedian day 60,230 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OKYO · Home | $1.07 USD | -0.03 (-2.7%) | 76,391 | $1.13 | $1.25 | $1.04 | $1.10 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OKYO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.07 | -0.03 | -2.7% | $1.13 | $1.25 | $1.04 | 76,391 | |
| $1.10 | -0.005 | -0.5% | $1.10 | $1.14 | $1.08 | 235,407 | |
| $1.105 | -0.07 | -6.0% | $1.18 | $1.20 | $1.105 | 167,321 | |
| $1.175 | -0.175 | -13.0% | $1.30 | $1.345 | $1.15 | 3,710,017 | |
| $1.35 | -0.05 | -3.6% | $1.41 | $1.41 | $1.204 | 264,095 | |
| $1.40 | -0.02 | -1.4% | $1.39 | $1.41 | $1.33 | 119,416 | |
| $1.42 | +0.04 | +2.9% | $1.357 | $1.449 | $1.311 | 59,877 | |
| $1.38 | +0.10 | +7.8% | $1.29 | $1.407 | $1.29 | 104,256 | |
| $1.28 | -0.15 | -10.5% | $1.40 | $1.42 | $1.28 | 118,455 | |
| $1.43 | +0.03 | +2.1% | $1.40 | $1.46 | $1.282 | 93,889 | |
| $1.40 | -0.03 | -2.1% | $1.41 | $1.41 | $1.35 | 50,490 | |
| $1.43 | -0.02 | -1.4% | $1.48 | $1.519 | $1.36 | 94,428 | |
| $1.45 | -0.01 | -0.7% | $1.448 | $1.465 | $1.41 | 26,869 | |
| $1.46 | -0.01 | -0.7% | $1.46 | $1.50 | $1.36 | 91,929 | |
| $1.47 | -0.03 | -2.0% | $1.46 | $1.49 | $1.40 | 107,088 | |
| $1.50 | +0.01 | +0.7% | $1.46 | $1.51 | $1.46 | 18,806 | |
| $1.49 | 0.00 | 0.0% | $1.48 | $1.535 | $1.40 | 24,651 | |
| $1.49 | +0.05 | +3.5% | $1.475 | $1.51 | $1.41 | 11,310 | |
| $1.44 | +0.04 | +2.9% | $1.40 | $1.44 | $1.39 | 16,653 | |
| $1.40 | -0.07 | -4.8% | $1.46 | $1.47 | $1.40 | 13,800 | |
| $1.47 | -0.07 | -4.5% | $1.50 | $1.50 | $1.38 | 72,500 | |
| $1.54 | +0.17 | +12.4% | $1.52 | $1.65 | $1.43 | 241,000 | |
| $1.37 | -0.03 | -2.1% | $1.41 | $1.42 | $1.37 | 48,200 | |
| $1.40 | -0.01 | -0.7% | $1.382 | $1.42 | $1.38 | 24,100 | |
| $1.41 | -0.02 | -1.4% | $1.43 | $1.43 | $1.40 | 25,600 | |
| $1.43 | +0.015 | +1.1% | $1.42 | $1.46 | $1.40 | 48,900 | |
| $1.415 | -0.023 | -1.6% | $1.45 | $1.45 | $1.38 | 18,500 | |
| $1.438 | -0.002 | -0.1% | $1.46 | $1.47 | $1.41 | 20,900 | |
| $1.44 | +0.02 | +1.4% | $1.46 | $1.49 | $1.40 | 70,400 | |
| $1.42 | +0.03 | +2.2% | $1.40 | $1.53 | $1.35 | 115,500 | |
| $1.39 | -0.02 | -1.4% | $1.43 | $1.46 | $1.35 | 27,500 | |
| $1.41 | -0.05 | -3.4% | $1.45 | $1.48 | $1.36 | 33,700 | |
| $1.46 | -0.01 | -0.7% | $1.48 | $1.49 | $1.46 | 30,400 | |
| $1.47 | 0.00 | 0.0% | $1.46 | $1.47 | $1.43 | 11,200 | |
| $1.47 | +0.13 | +9.7% | $1.33 | $1.47 | $1.33 | 82,500 | |
| $1.34 | +0.05 | +3.9% | $1.29 | $1.345 | $1.265 | 16,900 | |
| $1.29 | -0.07 | -5.1% | $1.34 | $1.36 | $1.29 | 6,000 | |
| $1.36 | -0.01 | -0.7% | $1.30 | $1.37 | $1.30 | 44,000 | |
| $1.37 | -0.01 | -0.7% | $1.355 | $1.39 | $1.31 | 141,700 | |
| $1.38 | 0.00 | 0.0% | $1.36 | $1.40 | $1.32 | 87,700 | |
| $1.38 | +0.06 | +4.5% | $1.33 | $1.39 | $1.30 | 87,100 | |
| $1.32 | -0.03 | -2.2% | $1.37 | $1.37 | $1.30 | 85,200 | |
| $1.35 | +0.02 | +1.5% | $1.34 | $1.38 | $1.31 | 98,700 | |
| $1.33 | -0.03 | -2.2% | $1.38 | $1.41 | $1.286 | 127,900 | |
| $1.36 | +0.04 | +3.0% | $1.32 | $1.44 | $1.32 | 22,100 | |
| $1.32 | -0.01 | -0.8% | $1.33 | $1.395 | $1.285 | 55,700 | |
| $1.33 | -0.01 | -0.7% | $1.36 | $1.42 | $1.28 | 86,000 | |
| $1.34 | -0.06 | -4.3% | $1.42 | $1.43 | $1.32 | 83,300 | |
| $1.40 | 0.00 | 0.0% | $1.38 | $1.455 | $1.35 | 133,800 | |
| $1.40 | -0.03 | -2.1% | $1.46 | $1.47 | $1.39 | 53,700 | |
| $1.43 | -0.02 | -1.4% | $1.40 | $1.47 | $1.40 | 145,900 | |
| $1.45 | -0.08 | -5.2% | $1.53 | $1.53 | $1.39 | 80,200 | |
| $1.53 | -0.04 | -2.5% | $1.56 | $1.59 | $1.395 | 275,700 | |
| $1.57 | +0.02 | +1.3% | $1.55 | $1.595 | $1.52 | 32,600 | |
| $1.55 | -0.07 | -4.3% | $1.62 | $1.62 | $1.521 | 9,300 | |
| $1.62 | +0.11 | +7.3% | $1.516 | $1.66 | $1.516 | 91,500 | |
| $1.51 | -0.01 | -0.7% | $1.52 | $1.55 | $1.51 | 22,300 | |
| $1.52 | -0.15 | -9.0% | $1.65 | $1.669 | $1.51 | 63,900 | |
| $1.67 | +0.12 | +7.7% | $1.599 | $1.67 | $1.48 | 135,400 | |
| $1.55 | 0.00 | 0.0% | $1.54 | $1.58 | $1.53 | 57,300 | |
| $1.55 | -0.01 | -0.6% | $1.55 | $1.58 | $1.53 | 6,400 | |
| $1.56 | +0.06 | +4.0% | $1.52 | $1.62 | $1.49 | 60,230 | |
| $1.50 | -0.04 | -2.6% | $1.55 | $1.56 | $1.49 | 38,552 | |
| $1.54 | +0.02 | +1.3% | $1.52 | $1.56 | $1.52 | 14,700 | |
| $1.52 | +0.01 | +0.7% | $1.51 | $1.548 | $1.48 | 10,900 |
- Ticker
- NASDAQ:OKYO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London
Latest deck · Feb 13, 2026
Investor Presentation (February 2026)
Investor deck · 28 slides
Latest news
OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London
Nov 12, 2026
Closed $1.40 (-1.4%) on Nov 12, 2026
OKYO Pharma to Present at the Stifel 2026 Healthcare Conference
Nov 5, 2026
Closed $1.40 (-2.1%) on Nov 5, 2026
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
Oct 6, 2026
Closed $1.46 (-0.7%) on Oct 6, 2026
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
Sep 29, 2026
Closed $1.36 (-0.7%) on Sep 29, 2026
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
Sep 9, 2026
Closed $1.45 (-5.2%) on Sep 9, 2026
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
Sep 8, 2026
Closed $1.53 (-2.5%) on Sep 8, 2026
Amendment to Annual Report by Foreign Issuer (Form 20-F/A)
Aug 7, 2026
Closed $1.57 (+5.4%) on Aug 10, 2026
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
Jul 28, 2026
Closed $1.64 (0.0%) on Jul 28, 2026
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
Jul 27, 2026
Closed $1.64 (+5.8%) on Jul 27, 2026
OKYO Pharma Announces Purchase of Shares by Director
Jul 23, 2026
Closed $1.48 (-2.6%) on Jul 23, 2026
OKYO Pharma Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 35 in the last 12 months · 42 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 15 decks · latest Feb 13, 2026
Where OKYO Pharma Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OKYO · Home listing · This page | NASDAQ | United States | USD |
| gettex:OK11 | gettex | Germany | EUR |
| BOATS:OKYO | BOATS | United States | USD |
| Munich:OK11 | Munich | Germany | EUR |
Valuation
Price/book 4.5× against a median of 1.8×: 8th lowest of 9 Biotechnology companies shown. Statements: Year to Mar 31, 2026 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $35.56M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.02
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| OKYO Pharma Limited · NASDAQ:OKYO | US$56.15M | US$35.56M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.02 |
| iNtRON Biotechnology, Inc. · KRX:048530 | US$57.38M | US$31.38M | n/a | 5.8× | n/a | 1.2× | −142.6% | 0.0× | n/a |
| HeXun Biosciences Co Ltd · TPEX:6986 | US$57.20M | US$32.05M | 16.2× | 3.4× | 6.5× | 1.8× | 37.7% | 0.0× | n/a |
| Tenax Therapeutics, Inc. · NASDAQ:TENX | US$56.92M | −US$56.78M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.35 |
| Kazia Therapeutics Ltd · NASDAQ:KZIA | US$56.22M | US$10.36M | n/a | 373× | n/a | 1.8× | n/a | 0.0× | 2.31 |
| Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704 | US$55.77M | US$51.65M | n/a | 9.1× | n/a | 2.5× | −43.0% | 0.3× | n/a |
| EyeGene, Inc. · KRX:185490 | US$55.57M | US$26.66M | n/a | 8.0× | n/a | 1.5× | −391.5% | 0.0× | n/a |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Median of the others | US$55.67M | US$31.71M | 16.2× | 9.1× | 6.5× | 1.8× | −132.6% | 0.0× | 1.82 |
Forecasts
2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.33 USD · Analysts' mean
- EPS, year to Mar 2027
- -0.12 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Robert Dempsey | Chief Executive Officer/Director |
| Keeren Shah | Chief Financial Officer |
| Paul Spencer | Business Development and Investor Relations |
| Flavio Mantelli | Chief Medical Officer |
| Gary Jacob | Chief Development Officer/Director |
| Raj Patil | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Gabriele Cerrone | Non-Executive Chairman |
| Bernard Denoyer | Non-Executive Director |
| Gary Jacob | Chief Development Officer/Director |
| John Brancaccio | Non-Executive Director |
| Robert Dempsey | Chief Executive Officer/Director |
| Willy Simon | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2025 | Feb 25, 2026 | +3.0% |
| Q1 2026 | Aug 5, 2025 | −1.3% |
| Q3 2025 | Jan 29, 2025 | +6.2% |
| Q1 2025 | Jul 30, 2024 | −1.6% |
| Q3 2024 | Jan 9, 2024 · After close | −4.0% |
| Q2 2024 | Dec 28, 2023 · Before open | +2.7% |
| Q1 2024 | Aug 15, 2023 · Before open | +3.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2026) | Investor deck | 28 slides | Feb 13, 2026 |
| Investor Presentation (June 2025) | Investor deck | 23 slides | June 2025 |
| Investor Presentation (July 2024) | Investor deck | 36 slides | July 2024 |
| Investor Presentation (May 2024) | Investor deck | 37 slides | May 2024 |
| Eyecelerator Conference (April 2024) | Conference | 14 slides | Apr 4, 2024 |
| Biotech Showcase 2024 | Conference | 22 slides | Jan 9, 2024 |
| Investor Presentation (October 2023) | Investor deck | 23 slides | October 2023 |
| Investor Presentation (September 2023) | Investor deck | 21 slides | September 2023 |
| Investor Presentation (July 2023) | Investor deck | 27 slides | July 2023 |
| Investor Presentation (June 2023) | Investor deck | 25 slides | June 2023 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2023) | Investor deck | 25 slides | May 2023 |
| Investor Presentation (January 2023) | Investor deck | 25 slides | January 2023 |
| Investor Presentation (May 2022) | Investor deck | 22 slides | May 2022 |
| West African Minerals — Mining Indaba 2016 | Conference | 18 slides | Feb 5, 2016 |
| West African Minerals — Investment Discovery Forum - Mining Indaba 2015 | Conference | 20 slides | February 2015 |
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares Announced: US$20M–US$23M · US$1.85 a share · Piper Sandler & Co. Dealers: Piper Sandler & Co. (lead) Use of proceeds: Clinical development of its product candidates, general corporate purposes and working capital | Feb 13, 2026 |
| At-the-market programme of common shares Announced: Leerink Partners LLC Dealers: Leerink Partners LLC (lead) Use of proceeds: Support ongoing clinical development and corporate objectives | Feb 11, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 an ADS on May 16, 2022.
- Price
- US$4.00 an ADS
- ADSs offered
- 625,000 American depositary shares
- Offering size
- US$2.5 million
- Underwriters' option
- Up to 93,750 more ADSs
- Listing
- OKYO on the Nasdaq Capital Market
- Underwriter
- ThinkEquity
- ADSs delivered
- On or about May 19, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 22, 2021 |
| Filed publicly | Mar 4, 2022 |
| Amended 6 times | Newest May 13, 2022 |
| Shares registered with an exchange | May 10, 2022 |
| Declared effective by the SEC | May 16, 2022 |
| Final prospectus, with the price | May 18, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 18, 2022 |
| EFFECT · Notice that a registration is effective | May 16, 2022 |
| FWP · Free writing prospectus | May 13, 2022 |
| F-1/A · Registration statement, amended | May 13, 2022 |
| CORRESP · Letter to the SEC | May 12, 2022 |
| CORRESP · Letter to the SEC | May 12, 2022 |
| CORRESP · Letter to the SEC | May 12, 2022 |
| CERT · Exchange's certificate of listing | May 12, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | May 10, 2022 |
| CORRESP · Letter to the SEC | May 10, 2022 |
All 30 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 10, 2022 |
| F-1/A · Registration statement, amended | May 9, 2022 |
| F-1/A · Registration statement, amended | May 4, 2022 |
| FWP · Free writing prospectus | Apr 29, 2022 |
| F-1/A · Registration statement, amended | Apr 26, 2022 |
| F-1/A · Registration statement, amended | Apr 14, 2022 |
| F-1/A · Registration statement, amended | Mar 25, 2022 |
| CORRESP · Letter to the SEC | Mar 25, 2022 |
| UPLOAD · Letter from the SEC | Mar 18, 2022 |
| F-1 · Registration statement | Mar 4, 2022 |
| DRS/A · Draft registration statement, amended | Nov 10, 2021 |
| DRSLTR · Letter to the SEC with a draft | Nov 9, 2021 |
| UPLOAD · Letter from the SEC | Sep 8, 2021 |
| DRSLTR · Letter to the SEC with a draft | Aug 23, 2021 |
| DRS · Draft registration statement | Aug 23, 2021 |
| UPLOAD · Letter from the SEC | Jun 7, 2021 |
| DRS/A · Draft registration statement, amended | May 21, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 21, 2021 |
| UPLOAD · Letter from the SEC | Apr 16, 2021 |
| DRS · Draft registration statement | Mar 22, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed May 18, 2022
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 6.69M | 2.56K | 7.51M | 6.75M | 13.0K | 811.5K | 5.97K | 219 | ||
| Gross profit | -6.69M | -2.56K | -7.51M | -6.75M | -13.0K | -811.5K | -5.97K | -219 | ||
| Research and development | 1.81M | 2.25M | 8.24M | 6.34M | 1.61M | 348.3K | 518.1K | 3.04M | ||
| Selling, general and administrative | 4.92M | 886.9K | 573.4K | 363.2K | ||||||
| Operating income | -8.50M | -7.19M | -15.7M | -13.1M | -6.23M | -4.13M | -1.52M | -4.54M | -28.3M | -363.3K |
| Depreciation and amortization | 1.82K | 2.56K | 3.87K | 3.80K | 2.42K | 1.51K | 212 | 218 | 1.04M | 364.8K |
| EBITDA | -8.50M | -7.19M | -15.7M | -13.1M | -6.23M | -4.13M | -1.52M | -4.54M | -27.2M | 1.54K |
| Interest expense | 473.9K | 878.2K | 1.05M | 96.7K | 0 | 1.12K | 1.16K | 0 | 0 | 3.54K |
| Income before tax | -8.94M | -7.97M | -16.8M | -13.3M | -6.22M | -3.38M | -1.62M | -4.90M | -28.3M | -241.9K |
| Income tax | 7.99K | 3.26M | -22.4K | 12.2K | 786.5K | 25.0K | 76.3K | -172.0K | 1 | -100.8K |
| Net income | -8.95M | -4.71M | -16.8M | -13.3M | -5.43M | -3.35M | -1.54M | -4.89M | -28.3M | -241.9K |
| Earnings per share, basic | -0.24 | -0.20 | -0.57 | -0.61 | -0.36 | -0.32 | -0.17 | -0.62 | -4.80 | -0.04 |
| Earnings per share, diluted | -0.20 | -0.57 | -0.61 | -0.36 | -0.32 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.6M | 1.56M | 826.8K | 4.05M | 2.70M | 6.89M | 235.5K | 627.6K | 2.01M | 3.93M |
| Short-term investments | 6.00M | 0 | 16.9M | |||||||
| Receivables | 170.7K | 1.89M | 580.9K | 592.2K | 813.0K | 43.4K | 326.2K | 111.4K | 48 | 153.9K |
| Inventory | 170.3K | -1.49K | 34 | -792 | 126 | 4.59K | ||||
| Current assets | 21.0M | 3.68M | 1.54M | 5.20M | 4.30M | 6.99M | 566.7K | 758.8K | 48 | 16.9M |
| Property, plant and equipment | 2.04K | 3.35K | 7.22K | 5.22K | 6.06K | 24.8K | 847 | |||
| Goodwill | 535.4K | |||||||||
| Total assets | 21.0M | 3.68M | 1.54M | 5.20M | 4.30M | 7.09M | 597.4K | 759.9K | 2.01M | 27.8M |
| Accounts payable | 7.14M | 8.37M | 7.06M | 4.26M | 1.31M | 1.67M | 593.7K | 381.8K | 141.8K | |
| Current liabilities | 8.64M | 9.23M | 7.42M | 7.26M | 1.35M | 1.71M | 710.7K | 426.7K | 91.1K | 258.8K |
| Total debt | 2.22M | 98.8K | 25.6K | |||||||
| Total liabilities | 8.64M | 9.23M | 7.42M | 7.26M | 1.35M | 1.77M | 737.2K | 426.7K | 91.1K | 258.8K |
| Shareholders' equity | 12.3M | -5.55M | -5.88M | -2.05M | 2.95M | 5.32M | -140.1K | 333.1K | 1.92M | 27.5M |
| Shares outstanding | 37.4M | 39.5M | 29.3M | 22.3M | 15.1M | 10.3M | 9.16M | 7.91M | 5.89M | 5.86M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M | -1.60M | -1.20M | -1.99M | -1.59M | -651.3K |
| Capital spending | -6.08K | -1.21K | -3 | -5.92K | -1.67K | -6.94K | -5.03K | -1.32K | -1.01K | -375.4K |
| Free cash flow | -5.94M | -1.81M | -9.49M | -7.70M | -5.47M | -1.61M | -1.20M | -1.99M | -1.59M | -1.03M |
| Cash from investing | -6.01M | -1.21K | -5.92K | -1.67K | -18.1K | -132.7K | -1.32K | -1.01K | -375.4K | |
| Cash from financing | 25.0M | 2.66M | 6.21M | 9.32M | 2.15M | 7.83M | 963.3K | 774.3K | 774.3K | 4.42K |
| Change in cash | 13.0M | 843.6K | -3.28M | 1.62M | -3.32M | 6.21M | -371.4K | -1.99M | -1.59M | -651.3K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 20, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 6, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 8, 2026 | Current report | SEC |
| 20-F/A · Annual report, amended | Aug 7, 2026 | Annual report | SEC |
| 4/A · Change in ownership, amended | Aug 7, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 7, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 313 filings. Open Filings
Cap table
Built by 6ix from OKYO Pharma Limited’s releases · as of Feb 13, 2026
- Common shares
- 52,479,527
- Fully diluted
- 52,479,527
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 52,479,527 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 52,479,527 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gary Jacob Other companies: Virpax Pharmaceuticals, Inc. (Director · Feb 16, 2021 – Jan 1, 2022 · Past); Hepion Pharmaceuticals, Inc. (Director · Oct 7, 2013 – Feb 19, 2024 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 23, 2021 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past) | Chief Development Officer/Director · Since at least May 16, 2022 |
| Gabriele Cerrone Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); Tiziana Life Sciences Ltd (Executive Chairman · Since at least Jun 15, 2026) | Non-Executive Chairman · Since at least Jul 21, 2026 |
| John Brancaccio Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 5, 2026); Tiziana Life Sciences Ltd (Non-Executive Director · Since at least Nov 5, 2026) | Non-Executive Director · Since at least Mar 18, 2026 |
| Keeren Shah Other companies: Tiziana Life Sciences Ltd (Chief Operating Officer & Chief Financial Officer · Since at least Mar 18, 2026); Accustem Sciences Inc (Chief Finance Officer · Since at least Dec 1, 2021) | Chief Financial Officer · Since at least May 16, 2022 |
| Willy Simon Other companies: Accustem Sciences Inc (Board Member · Since at least Nov 4, 2026); Tiziana Life Sciences Ltd (Non-Executive Director · Since at least Nov 4, 2026) | Non-Executive Director · Since at least Nov 4, 2026 |
| Paul Spencer Other companies: Tiziana Life Sciences Ltd (Business Development, and Investor Relations · Since at least Oct 21, 2026) | Business Development and Investor Relations · Since at least Oct 6, 2026 |
| Bernard Denoyer | Non-Executive Director · Since at least Mar 18, 2026 |
| Flavio Mantelli | Chief Medical Officer · Since at least Feb 10, 2026 |
| Rajkumar V Patil | Chief Scientific Officer · Since at least Mar 18, 2026 |
| Raj Patil | Chief Scientific Officer · Since at least Jul 28, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Robert Dempsey | Chief Executive Officer/Director · Since at least Jul 22, 2026 |
Log in to ask 6ix AI your own questions about OKYO Pharma Limited.